KATHLEEN BAXLEY: Open Payments
NPI 1023599560 · WEST COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$961 in 53 payments from 19 companies in 2025. Trend: 2023 $498 · 2024 $757 · 2025 $961
Food & beverage: $961
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $234 |
| ABBVIE INC. | 12 | $153 |
| PFIZER INC. | 5 | $79 |
| AstraZeneca Pharmaceuticals LP | 4 | $59 |
| Sumitomo Pharma America, Inc. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Dynavax Technologies Corporation | 2 | $51 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $46 |
| Zimmer Biomet Holdings, Inc. | 1 | $40 |
| Lilly USA, LLC | 2 | $31 |
Products named: Ozempic, VRAYLAR, Wegovy, UBRELVY, GEMTESA, REXULTI, Heplisav-B, XIFAXAN.
Industry payments across SC — which companies pay providers there.
